Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 403 in Osteoarthritis Knee Pain
NCT02318407Phase 1Completed
- Sponsor
- Amgen
- Start
- Dec 2006
- Primary completion
- Jan 2008
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing AMG 403 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events, clinically significant changes in vital signs, physical examinations, clinical laboratory safety tests, and ECGs. Started Dec 2006; status: completed.
02
Drugs
fulranumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02318407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318407.